SCHEMBL18286014

SCHEMBL18286014

CCNCCC(=O)Nc1sc2c(c1-c1nc3cc(Br)ccc3s1)CCN(C(=O)O)C2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
KDM4E B2RXH2 3/20 0.56
ALDH1A1 P00352 2/20 0.56
NPC1 O15118 2/20 0.56
NPSR1 Q6W5P4 1/20 0.56
APEX1 P27695 5/20 0.50
LMNA P02545 3/20 0.48
TP53 P04637 2/20 0.48
MEN1 O00255 2/20 0.47
HTT P42858 2/20 0.47
KMT2A Q03164 2/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
MYC P01106 6/20 0.45
UHRF1 Q96T88 1/20 0.45
USP2 O75604 1/20 0.44
POLB P06746 1/20 0.44
RECQL P46063 1/20 0.44
RAB9A P51151 1/20 0.44
BLM P54132 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18293173 0.90 MAPT (0.52) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL18286001 0.89 MAPT (0.54) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL18286000 0.89 MAPT (0.54) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL18285701 0.88 APEX1 (0.60) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL20240015 0.83 MAPT (0.49) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL20240005 0.82 MAPT (0.52) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL18286046 0.82 MAPT (0.49) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL18286092 0.82 MAPT (0.52) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL20239973 0.81 MAPT (0.48) MAPTKDM4EALDH1A1NPC1NPSR1
SCHEMBL22449465 0.81 MAPT (0.45) MAPTKDM4EALDH1A1NPC1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
US-20210188833-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2021-06-24 US disclosed
US-10787444-B2 Compounds for the modulation of myc activity SYROS PHARMACEUTICALS, INC. (US) 2020-09-29 US disclosed
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-06-14 US disclosed
WO-2016197078-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS, INC. (US) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 MAPT 104/4885KDM4E 4565/4885ALDH1A1 2091/4885
US-20210188833-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 MAPT 131/4885KDM4E 4623/4885ALDH1A1 2768/4885
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 MAPT 131/4885KDM4E 4623/4885ALDH1A1 2768/4885
US-10787444-B2 Compounds for the modulation of myc activity MYC, MYCBP, MYCBP2 MAPT 104/4885KDM4E 4565/4885ALDH1A1 2091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.